Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Y-mAbs Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Y-mAbs Therapeutics, Inc.

YMAB

Y-mAbs Therapeutics, Inc.

About Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics is a biopharmaceutical company specializing in developing and commercializing innovative antibody-based and radioimmunotherapy cancer treatments. Its core product, DANYELZA, targets GD2-positive tumors, primarily in pediatric neuroblastoma, with ongoing trials for other cancers. The company leverages proprietary platforms and collaborations with leading research institutions to address unmet medical needs in oncology through targeted therapies.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Y-mAbs Therapeutics, Inc.

1
1
Y-mAbs Therapeutics, Inc. Y-mAbs Reports 14% Revenue Decline and $3.2 Million Net Loss in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
Y-mAbs Therapeutics, Inc. Y-mAbs Therapeutics Reports 8% Revenue Growth in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Y-mAbs Therapeutics, Inc. Y-mAbs Therapeutics Reports Decline in Revenues and Increased Net Losses for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments